Jump to navigation
About
Mission and Values
Leadership Team
Board of Directors
Medical Advisors
Focus
Hyperoxaluria
Systemic Oxalosis
Hyperuricemia
Publications
Products
Reloxaliase
ALLN-346
Pipeline
FAQs
Investors
Overview
News Releases
Events and Presentations
Stock Information
Analyst Coverage
Corporate Governance
SEC Filings
Shareholder Services
Careers
Contact
Home
Dedicated to Treating Patients
With Rare and Severe
Metabolic Diseases
Utilizing the GI Tract
to Reduce the Burden
of Metabolic Disease
Understanding
Metabolic Diseases
that Affect the Kidney
News
October 17, 2019
Allena Pharmaceuticals to Present New Data on Reloxaliase and ALLN-346 Development Programs at Upcoming ASN Kidney Week and ACR/ARP Annual Meeting
Read more
about Allena Pharmaceuticals to Present New Data on Reloxaliase and ALLN-346 Development Programs at Upcoming ASN Kidney Week and ACR/ARP Annual Meeting
September 16, 2019
Allena Pharmaceuticals Completes Enrollment in Pivotal Phase 3 URIROX-1 Trial Evaluating Reloxaliase in Patients with Enteric Hyperoxaluria
Read more
about Allena Pharmaceuticals Completes Enrollment in Pivotal Phase 3 URIROX-1 Trial Evaluating Reloxaliase in Patients with Enteric Hyperoxaluria
September 11, 2019
Allena Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Enteric Hyperoxaluria and Potential for Reloxaliase
Read more
about Allena Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Enteric Hyperoxaluria and Potential for Reloxaliase
